Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.

BACKGROUND

Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.

METHODS

A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.

RESULTS

Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.

CONCLUSION

Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.